[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biliary-tract-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biliary-tract-diseases":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,62,91,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":34,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100635757","outcomes-after-liver-and-biliary-resection-at-a-high-volume-center-100635757",false,"NCT07556835","Outcomes After Liver and Biliary Resection at a High-Volume Center","Ambispective Cohort Study of Clinical and Oncologic Outcomes in Patients Undergoing Liver and Biliary Resection at San Jacopo Hospital, Pistoia","BILIVER","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients undergoing liver resection and\u002For biliary resection at San Jacopo Hospital, Pistoia\n* Diagnosis of benign or malignant hepatobiliary disease\n* Availability of clinical, surgical, and follow-up data\n* For the prospective cohort, provision of written informed consent when required according to local regulations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy\n* No liver or biliary resection performed\n* Biopsy only without resection\n* Refusal or unavailability of consent for the prospective cohort when consent is required","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and\u002For biliary resection for benign and malignant diseases.\n\nThis study evaluates postoperative morbidity and mortality within 90 days after surgery, as well as overall survival and disease-free survival in patients with malignant disease.\n\nParticipants will:\n\n* undergo standard surgical and perioperative management according to routine clinical practice\n* have clinical, surgical, and follow-up data collected from institutional medical records\n* be followed for postoperative outcomes and long-term oncologic outcomes up to 5 years",[25,26,27,28,29,30,31,32,33],"Liver Neoplasms","Hepatobiliary Diseases","Cholangiocarcinoma","Hepatocellular Carcinoma","Liver Metastases From Colorectal Cancer","Liver Metastases","Biliary Tract Diseases","Benign Liver Disease","Gallbladder Carcinoma",[35,36,37,38,39,40,41,42,43,44,45,46,47,48,27],"Hepatobiliary surgery","Liver resection","Biliary resection","Hepatectomy","Postoperative complications","Postoperative mortality","Clavien-Dindo classification","Overall survival","Disease-free survival","Surgical outcomes","Observational study","Ambispective cohort","CRLM","HCC","NOT_YET_RECRUITING","2026-04-22",{"date":52,"type":53},"2026-04-29","ACTUAL",{"date":55,"type":21},"2026-04",{"date":57,"type":21},"2036-12",{"name":59,"class":60},"Azienda USL Toscana Centro","OTHER",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":61},"100568629","smartglass-guided-ercp-with-cannulation-of-native-papilla-10-100568629","NCT06683716","SmartGlass-Guided ERCP with Cannulation of Native Papilla 1.0","Remote Assistance Via Smart Glasses Compared to In-person Assistance for Cannulation of the Native Papilla During Endoscopic Retrograde Cholangiopancreatography","EmeRald","Inclusion criteria\n\n* Adult patients aged ≥ 18 years without previous papillotomy Exclusion criteria\n* Cannulation of the minor papilla necessary\n* Significant comorbidity\n* Haemodynamic instability\n* Pregnant women\n* Refusal or inability to give written informed consent for the study\n* Instructor had to perform the examination himself\u002Fherself",{"count":71,"type":21},170,"INTERVENTIONAL",[74],"NA","The aim of this prospective randomized study is to evaluate whether telemedical assistance via SmartGlasses is equivalent to physical presence in teaching Endoscopic Retrograde Cholangiopancreaticography (ERCP) in terms of examination success and safety. Endoscopic papilla cannulation is a key skill for successful ERCP and therefore a measurable primary endpoint of the study. This can be measured as the time (in seconds\u002Fminutes) between stable visualization of the papilla and successful endoscopic cannulation of the target structure (bile duct or pancreatic duct).",[31,77],"Pancreatic Diseases",[79,80,81],"Telemedicine","Training Technique","Cholangiopancreatography, Endoscopic Retrograde","2024-11-08",{"date":84,"type":53},"2024-11-12",{"date":86,"type":21},"2025-01-02",{"date":88,"type":21},"2026-12-31",{"name":90,"class":60},"Helios Kliniken Schwerin",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100537309","construction-of-multicenter-retrospective-registry-cohort-database-for-gallbladder-cancer-100537309","NCT06276153","Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer","CRGGCext","Inclusion Criteria:\n\n* Sign informed consent, have good compliance, and be willing to accept follow-up and provide blood samples\n* Age 18-74 years old, gender is not limited\n* Clinical diagnosis of gallbladder cancer, including unoperated patients preliminarily diagnosed as gallbladder cancer according to the results of imaging examinations and laboratory tests, or pathological examination of patients treated with surgery confirmed as malignant tumors of the gallbladder.\n* The primary tumor is located in gallbladder floor, gallbladder body, gallbladder neck or gallbladder duct.\n* Karnofsky performance score greater than 50.\n\nExclusion Criteria:\n\n* Patients with gallbladder cancer, gallbladder cancer foci are not primary lesions.\n* Patients with gallbladder cancer, combined with serious central nervous system diseases, respiratory diseases, autoimmune diseases, chronic renal insufficiency and other diseases, long-term use of immunosuppressants, combined with serious uncontrolled infections.\n* Patients with gallbladder cancer, who also have active cardiovascular and cerebrovascular diseases, have cerebrovascular accidents, myocardial infarction, unstable angina pectoris, or grade II. or above congestive heart failure according to the standards of the New York Heart Association, and require serious arrhythmias requiring drug treatment.\n* Patients with gallbladder cancer, women of childbearing age who have a positive blood pregnancy test or have not had a pregnancy test, pregnant or breastfeeding women.\n* The patient is participating in other therapeutic clinical trials where treatment measures cannot be clarified or treatment information cannot be collected .","74 Years",{"count":100,"type":21},5000,"The aim of the study is to establishing a standardized clinical information database for patients with malignant tumors of gallbaldder. Based on the database, real-world clinical research on the diagnosis and treatment of biliary tract tumors is about to be carried out, and a high-standard cohort research foundation is laid for precision therapy.",[31,103,104],"Gallbladder Cancer","Gallbladder Neoplasms",[106,107,108,109,110],"gallbladder cancer","gallbladder neoplasms","cohort study","registry cohort","biliary tract neoplasms","2024-02-25",{"date":113,"type":53},"2024-02-28",{"date":115,"type":21},"2024-03-01",{"date":117,"type":21},"2029-02-28",{"name":119,"class":60},"RenJi Hospital",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":127,"targetDuration":129,"studyType":22,"phases":4,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100508172","the-construction-of-clinical-database-and-multiomics-biobank-based-on-a-multicentral-prospective-cohort-of-benign-and-malignant-biliary-tract-diseases-100508172","NCT05896956","The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases","The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases 胆道系统良恶性肿瘤前瞻性登记队列数据库与多组学生物样本库建设","Inclusion Criteria:\n\n1. Sign informed consent, have good compliance, and be willing to accept follow-up and provide blood samples.\n2. Age 18-74 years old, gender is not limited.\n3. Clinical diagnosis of benign and malignant tumors of the biliary system, including unoperated patients preliminarily diagnosed as benign and malignant tumors of the biliary tract according to the results of imaging examinations and laboratory tests, or pathological examination of patients treated with surgery confirmed as benign and malignant tumors of the gallbladder.\n4. The primary tumor is located in the extrahepatic bile duct, intrahepatic bile duct, gallbladder floor, gallbladder body, gallbladder neck or gallbladder duct.\n5. Karnofsky performance score greater than 50.\n\nExclusion Criteria:\n\n1. Patients with biliary malignant tumors, biliary malignant tumor foci are not primary lesions.\n2. Patients with biliary malignant tumors, combined with serious central nervous system diseases, respiratory diseases, autoimmune diseases, chronic renal insufficiency and other diseases, long-term use of immunosuppressants, combined with serious uncontrolled infections.\n3. Patients with biliary malignant tumors, who also have active cardiovascular and cerebrovascular diseases, have cerebrovascular accidents, myocardial infarction, unstable angina pectoris, or grade II. or above congestive heart failure according to the standards of the New York Heart Association, and require serious arrhythmias requiring drug treatment.\n4. Patients with biliary malignant tumors, women of childbearing age who have a positive blood pregnancy test or have not had a pregnancy test, pregnant or breastfeeding women.\n5. The patient is participating in other therapeutic clinical trials where treatment measures cannot be clarified or treatment information cannot be collected.",{"count":128,"type":21},500,"2 Years","The aim of the study is to establishing a standardized biobank and a clinical information database for patients with benign and malignant tumors of the biliary system. With follow-up plans and advanced multiomics technology, a multiomics database for patients with benign and malignant tumors of the biliary tract will be further established. Based on the above work, real-world clinical research on the diagnosis and treatment of biliary tract tumors is about to be carried out, and a high-standard cohort research foundation is laid for precision therapy based on multiomics characteristics and molecular typing of biliary tract tumors.",[31,103,132,133,134,135],"Extrahepatic Bile Duct Cancer","Intrahepatic Cholangiocarcinoma","Biliary Tract Neoplasms","Gall Stone",[137,106,110,138,108],"biliary tract diseases","biliary tract cancer","2023-06-01",{"date":141,"type":53},"2023-06-09",{"date":143,"type":21},"2023-07-01",{"date":145,"type":21},"2027-06-30",{"name":119,"class":60}]